Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Exclusion Criteria

• •GOG performance status (PS) 0-2 for patients who have receive one prior regimen OR GOG PS 0-1 for patients who have received 2-3 prior regimens
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Creatinine ≤ 1.5 times upper limit normal (ULN)
• •Bilirubin ≤ 1.5 times ULN
• •AST ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •No neuropathy (sensory and motor) \> grade 2
• •Fasting cholesterol \< 350 mg/dL
• •Fasting triglycerides \< 400 mg/dL
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active infection requiring antibiotics (with the exception of uncomplicated UTI)
• •No other invasive malignancies within the past 5 years, except for non-melanoma skin cancer, breast cancer, or head and neck cancer
• •See Disease Characteristics
• •Recovered from prior surgery, radiotherapy, or chemotherapy
• •At least 1 week since prior hormonal therapy directed at the malignant tumor
• •At least 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin
• •* Patient must remain free of recurrent or metastatic disease
• •At least 3 years since prior adjuvant chemotherapy for localized breast cancer
• •* Patient must remain free of recurrent or metastatic disease
• •At least 3 weeks since other prior therapy directed at the malignant tumor, including immunologic agents
• •No prior temsirolimus
• •No prior cancer treatment that would preclude study therapy
• •No prior radiotherapy to \> 25% of marrow-bearing areas
• •No prior radiotherapy to any portion of the abdominal cavity or pelvis, except for the treatment of ovarian cancer
• •No prior non-cytotoxic therapy for management of recurrent or persistent ovarian disease, except for therapy that was part of the primary treatment regimen
• •Two additional cytotoxic regimens (defined as any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa) for management of recurrent or persistent ovarian disease allowed
• •Concurrent low molecular weight heparin allowed provided PT/INR ≤ 1.5
• •Concurrent hormone replacement therapy allowed
• •No concurrent amifostine or other protective reagents
• •No concurrent prophylactic filgrastim (G-CSF)